Latest news

• Pricing pressures peg back Lilly’s growth products

  Lilly has other new medicines rolling out to help it manage the Cialis patent cliff, and third-to-market CGRP inhibitor for migraine – Emgality (galcanezumab) - added $14m in the quarter, overtaking

• Novartis and Amgen come to blows over migraine partnership

  It has since been followed by Teva’s Ajovy (fremanezumab) and Eli Lilly’s Emgality (galcanezumab), which have similar dosing requirements.

• Pfizer closes on EU approval of lung cancer drug Vizimpro

  The CHMP also backed Teva’s CGRP inhibitor Ajovy (fremanezumab) for migraine prevention, setting the drug on course to compete with earlier approvals Aimovig (erenumab) from Amgen/Novartis and Emgality (galcanezumab)

• NICE rejects Novartis migraine treatment Aimovig

  Novartis has a number of competitors in the CGRP class hot on its heels: Lilly's Emgality (galcanezumab) gained EU approval in November, and is now entering the NICE appraisal process.

• Teva wins FDA OK for crucial migraine drug

  ahead of late-stage rivals from Eli Lilly (galcanezumab) and Alder Biopharma (eptinezumab).